GeneBioTech (Korea) Probability of Future Stock Price Finishing Over 4,280
| 086060 Stock | KRW 3,270 140.00 4.11% |
GeneBioTech |
GeneBioTech Target Price Odds to finish over 4,280
The tendency of GeneBioTech Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3,270 | 90 days | 3,270 | more than 94.0 |
Based on a normal probability distribution, the odds of GeneBioTech to move above the current price in 90 days from now is more than 94.0 (This GeneBioTech Co probability density function shows the probability of GeneBioTech Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon GeneBioTech has a beta of 0.094. This suggests as returns on the market go up, GeneBioTech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding GeneBioTech Co will be expected to be much smaller as well. Additionally GeneBioTech Co has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. GeneBioTech Price Density |
| Price |
Predictive Modules for GeneBioTech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GeneBioTech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.GeneBioTech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GeneBioTech is not an exception. The market had few large corrections towards the GeneBioTech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GeneBioTech Co, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GeneBioTech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.09 | |
σ | Overall volatility | 105.52 | |
Ir | Information ratio | -0.04 |
GeneBioTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GeneBioTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GeneBioTech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GeneBioTech generated a negative expected return over the last 90 days | |
| The company reported the revenue of 62.81 B. Net Loss for the year was (484.4 M) with profit before overhead, payroll, taxes, and interest of 9.43 B. | |
| GeneBioTech Co has accumulated about 7.43 B in cash with (2.84 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
GeneBioTech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GeneBioTech Stock often depends not only on the future outlook of the current and potential GeneBioTech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GeneBioTech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.6 M | |
| Cash And Short Term Investments | 14.3 B |
GeneBioTech Technical Analysis
GeneBioTech's future price can be derived by breaking down and analyzing its technical indicators over time. GeneBioTech Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of GeneBioTech Co. In general, you should focus on analyzing GeneBioTech Stock price patterns and their correlations with different microeconomic environments and drivers.
GeneBioTech Predictive Forecast Models
GeneBioTech's time-series forecasting models is one of many GeneBioTech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary GeneBioTech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about GeneBioTech
Checking the ongoing alerts about GeneBioTech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for GeneBioTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| GeneBioTech generated a negative expected return over the last 90 days | |
| The company reported the revenue of 62.81 B. Net Loss for the year was (484.4 M) with profit before overhead, payroll, taxes, and interest of 9.43 B. | |
| GeneBioTech Co has accumulated about 7.43 B in cash with (2.84 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
Other Information on Investing in GeneBioTech Stock
GeneBioTech financial ratios help investors to determine whether GeneBioTech Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GeneBioTech with respect to the benefits of owning GeneBioTech security.